Arscience | Science

info@arsciencebio.com

ARScience Bio’s pipeline includes several cytokines and immunomodulators that enhance the activity of new cell therapy treatments by stimulating Treg proliferation and controlling side effects of the therapies for both leukemias and solid tumors.

Our pipeline also includes targets for several orphan diseases that provide affordable and improved therapeutic profiles against existing treatments.

Interleukins

Interleukins are a group of small signaling proteins, also known as cytokines, that are produced by various cells in the immune system. They play a vital role in regulating immune response by performing a range of functions, such as helping to locate foreign pathogens, driving the maturation and activation of immune cells and mediating cellular communication.

There are over 30 different types of interleukins, each with its own unique set of functions. Interleukins attach to specific receptors on the surfaces of immune cells, pathogens, and even tumor cells, triggering a series of events that can activate or suppress the immune system to stop damage.

It's increasingly clear that interleukins have value beyond the human immune system. Many tumors secrete factors that dampen T cell and other immune cell responses in their microenvironment, enabling these tumors to thrive. However, interleukins have the potential to activate protective immune cells, thus enabling the immune system to reverse the inhibitory effect of the tumor microenvironment and eliminate cancer. Not only that, but many of these immune cells rely on the presence of interleukins for their activity, making these interleukins essential components of immune responses. As research continues on these molecules, their potential applications in the treatment of cancer and other diseases are being explored.

cell-division-generic-cell-dividing-with-copy-spa-2022-11-02-18-17-26-utc (1)

Interleukins + Cell Therapy

Effector immune cells, such as T or NK cells, rely on signals provided by interleukins for their activity. Interleukins not only promote these cells’ activation, but also persistence and cytotoxicity against pathogens. Thus, interleukin availability is critical to cellular therapies, and providing these molecules in vivo can boost immune responses in therapeutic settings in remarkable ways.

Though interleukins have typically been used ex vivo to activate immune cells prior to adoptive transfer, a unique opportunity exists by providing interleukins directly in vivo. Combining in vivo interleukins with cell therapies can offer several advantages. In vivo interleukins can enhance the effectiveness of cell therapies by stimulating the immune response to recognize and attack cancer cells or other foreign pathogens. They can do this, firstly, by creating a more permissible environment for effector activity of adoptively transferred cellular therapies, and, secondly, by stimulating activation of bystander cells. They can also help to create a more favorable tumor microenvironment by suppressing immune-suppressive factors secreted by tumors, which can enable immune cells to better target and eliminate cancer cells. This can result in improved patient responses to immune-based cell therapies.

Partnering with ARSCIENCE BIOTHERAPEUTICS can provide early stage cell therapy companies with access to our in-vivo ready, industry-leading interleukin portfolio backed by our extensive experience with knowledge of interleukins. Our team has more than 20 years of experience developing and optimizing interleukins and we have a deep understanding of how interleukins can be combined with cell therapies to increase the chances of success in clinical trials and achieve better outcomes for patients. Overall, combining in vivo interleukins with cell therapies represents an exciting and promising approach to improve the efficacy of cell therapies for cancer and other immune-related diseases.

Product pipeline

Product	Technology	Indication	Status
ARS02	SC Low Dose \|\|-2	Monotherapy for multiple neurodegenerative conditions	IND
ARS02C	SC Low Dose \|\|-2 Combination	Combination of Treg-Based therapy across multiple therapeutic areas	Non clinical
ARS15	IL-15	Solid Tumors	FIH
ARS10	IL-15 - Fusion protein	Cancer	Pre clinical

If you need more information please contact us, a member of the team will contact you back as soon as possible.

2385 NW Executive Center Dr., Suite 100, Boca Raton, FL 33431

info@arsciencebio.com

Arscience Bio 2023

ARScience Bio’s team has over 20 years of experience in cytokine and immunomodulator development and manufacturing. We have built strong partnerships with leading academic institutions and clinical groups to develop novel indications for our portfolio of products.

Home

About us

People

Science

News

Contact